Protocol Ledger

NCT06593587 · Phase III · COMPLETED

A Study to Assess the Safety, Tolerability, and Immunogenicity of RSVpreF in Older Adults in Korea

Interventional Phase III clinical trial protocol NCT06593587 sponsored by Pfizer in Infectious Disease and Vaccines, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-10-07 Enrollment: 378 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT06593587
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)378 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06593587
Protocol FieldVerified Registry Value
NCT IdentifierNCT06593587
Consolidated Lead SponsorPfizer
Therapeutic Condition CohortInfectious Disease and Vaccines
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment378 participants (ACTUAL)
Registered Start Date2024-10-07
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06593587
Hospital Research SiteLocationSite Profile
Inha University HospitalIncheon, South KoreaOpen Hospital Dossier ->
Chonnam National University HospitalGwangju, South KoreaOpen Hospital Dossier ->
The Catholic University of Korea, St. Vincent's HospitalSuwon, South KoreaOpen Hospital Dossier ->
Ajou University HospitalSuwon, South KoreaOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Pfizer across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Infectious Disease and Vaccines Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI